Role for Neurokinin-2 Receptor in Interleukin-5-induced Airway Hyperresponsiveness but not Eosinophilia in Guinea Pigs

In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma. IL-5 seems to be a critical cytokine since it selectively affects eosinophil functions. The mechanism of action by which IL-5 leads to airway h...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 156; no. 2; pp. 367 - 374
Main Authors KRANEVELD, ALETTA D., NIJKAMP, FRANS P., VAN OOSTERHOUT, ANTOON J. M.
Format Journal Article
LanguageEnglish
Published New York, NY American Lung Association 01.08.1997
Subjects
Online AccessGet full text
ISSN1073-449X
1535-4970
DOI10.1164/ajrccm.156.2.9608101

Cover

Loading…
Abstract In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma. IL-5 seems to be a critical cytokine since it selectively affects eosinophil functions. The mechanism of action by which IL-5 leads to airway hyperresponsiveness may be important for our understanding of the pathogenesis of asthma. Neurogenic inflammation, which is mediated by nonadrenergic noncholinergic nerves (NANC), may play a role in the IL-5-induced effects in guinea pig airways. In this study, the role of neuropeptides in the IL-5-induced airway hyperresponsiveness and eosinophilia in the guinea pig was examined using selective neurokinin receptor antagonists. Intra-airway application of IL-5 (1 microgram, twice) induces a selective eosinophil migration (control: 12 [8-22] x 10(5) cells and IL-5: 90 [67-187] x 10(5) cells, p < 0.05) and activation (control: 6.3 +/- 0.9 ng eosinophil peroxidase [EPO]/ml bronchoalveolar lavage [BAL] fluid and IL-5: 29.3 +/- 4.9 ng EPO/ml BAL fluid, p < 0.05) and a pronounced airway hyperresponsiveness in vivo. The maximal responses to histamine are increased by 160 +/- 16% (p < 0.05) after IL-5. Treatment of guinea pigs with either the nonselective neurokinin (NK)-receptor antagonist, FK224, or the selective NK2-receptor antagonist, SR48968, results in a complete inhibition of the in vivo hyperresponsiveness found after application of IL-5. Vice versa, intra-airway administration of substance P (10 micrograms, twice) results in an airway hyperresponsiveness (increased maximal response after substance P: 166 +/- 15% [p < 0.05]) without inducing migration or activation of eosinophils. All examined NK-receptor antagonists do not influence the IL-5-induced eosinophil accumulation. In addition, no effect of the NK-receptor antagonists is observed on the IL-5-induced eosinophil activation, as determined by BAL fluid EPO levels. The release of NK2-receptor active tachykinins plays an important role in the development of IL-5-induced airway hyperresponsiveness. This feature appears to be a step following eosinophil infiltration and activation since there are no effects on eosinophil function by pretreatment of the used NK-receptor antagonists.
AbstractList In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma. IL-5 seems to be a critical cytokine since it selectively affects eosinophil functions. The mechanism of action by which IL-5 leads to airway hyperresponsiveness may be important for our understanding of the pathogenesis of asthma. Neurogenic inflammation, which is mediated by nonadrenergic noncholinergic nerves (NANC), may play a role in the IL-5-induced effects in guinea pig airways. In this study, the role of neuropeptides in the IL-5-induced airway hyperresponsiveness and eosinophilia in the guinea pig was examined using selective neurokinin receptor antagonists. Intra-airway application of IL-5 (1 microgram, twice) induces a selective eosinophil migration (control: 12 [8-22] x 10(5) cells and IL-5: 90 [67-187] x 10(5) cells, p < 0.05) and activation (control: 6.3 +/- 0.9 ng eosinophil peroxidase [EPO]/ml bronchoalveolar lavage [BAL] fluid and IL-5: 29.3 +/- 4.9 ng EPO/ml BAL fluid, p < 0.05) and a pronounced airway hyperresponsiveness in vivo. The maximal responses to histamine are increased by 160 +/- 16% (p < 0.05) after IL-5. Treatment of guinea pigs with either the nonselective neurokinin (NK)-receptor antagonist, FK224, or the selective NK2-receptor antagonist, SR48968, results in a complete inhibition of the in vivo hyperresponsiveness found after application of IL-5. Vice versa, intra-airway administration of substance P (10 micrograms, twice) results in an airway hyperresponsiveness (increased maximal response after substance P: 166 +/- 15% [p < 0.05]) without inducing migration or activation of eosinophils. All examined NK-receptor antagonists do not influence the IL-5-induced eosinophil accumulation. In addition, no effect of the NK-receptor antagonists is observed on the IL-5-induced eosinophil activation, as determined by BAL fluid EPO levels. The release of NK2-receptor active tachykinins plays an important role in the development of IL-5-induced airway hyperresponsiveness. This feature appears to be a step following eosinophil infiltration and activation since there are no effects on eosinophil function by pretreatment of the used NK-receptor antagonists.In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma. IL-5 seems to be a critical cytokine since it selectively affects eosinophil functions. The mechanism of action by which IL-5 leads to airway hyperresponsiveness may be important for our understanding of the pathogenesis of asthma. Neurogenic inflammation, which is mediated by nonadrenergic noncholinergic nerves (NANC), may play a role in the IL-5-induced effects in guinea pig airways. In this study, the role of neuropeptides in the IL-5-induced airway hyperresponsiveness and eosinophilia in the guinea pig was examined using selective neurokinin receptor antagonists. Intra-airway application of IL-5 (1 microgram, twice) induces a selective eosinophil migration (control: 12 [8-22] x 10(5) cells and IL-5: 90 [67-187] x 10(5) cells, p < 0.05) and activation (control: 6.3 +/- 0.9 ng eosinophil peroxidase [EPO]/ml bronchoalveolar lavage [BAL] fluid and IL-5: 29.3 +/- 4.9 ng EPO/ml BAL fluid, p < 0.05) and a pronounced airway hyperresponsiveness in vivo. The maximal responses to histamine are increased by 160 +/- 16% (p < 0.05) after IL-5. Treatment of guinea pigs with either the nonselective neurokinin (NK)-receptor antagonist, FK224, or the selective NK2-receptor antagonist, SR48968, results in a complete inhibition of the in vivo hyperresponsiveness found after application of IL-5. Vice versa, intra-airway administration of substance P (10 micrograms, twice) results in an airway hyperresponsiveness (increased maximal response after substance P: 166 +/- 15% [p < 0.05]) without inducing migration or activation of eosinophils. All examined NK-receptor antagonists do not influence the IL-5-induced eosinophil accumulation. In addition, no effect of the NK-receptor antagonists is observed on the IL-5-induced eosinophil activation, as determined by BAL fluid EPO levels. The release of NK2-receptor active tachykinins plays an important role in the development of IL-5-induced airway hyperresponsiveness. This feature appears to be a step following eosinophil infiltration and activation since there are no effects on eosinophil function by pretreatment of the used NK-receptor antagonists.
In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma. IL-5 seems to be a critical cytokine since it selectively affects eosinophil functions. The mechanism of action by which IL-5 leads to airway hyperresponsiveness may be important for our understanding of the pathogenesis of asthma. Neurogenic inflammation, which is mediated by nonadrenergic noncholinergic nerves (NANC), may play a role in the IL-5-induced effects in guinea pig airways. In this study, the role of neuropeptides in the IL-5-induced airway hyperresponsiveness and eosinophilia in the guinea pig was examined using selective neurokinin receptor antagonists. Intra-airway application of IL-5 (1 microgram, twice) induces a selective eosinophil migration (control: 12 [8-22] x 10(5) cells and IL-5: 90 [67-187] x 10(5) cells, p < 0.05) and activation (control: 6.3 +/- 0.9 ng eosinophil peroxidase [EPO]/ml bronchoalveolar lavage [BAL] fluid and IL-5: 29.3 +/- 4.9 ng EPO/ml BAL fluid, p < 0.05) and a pronounced airway hyperresponsiveness in vivo. The maximal responses to histamine are increased by 160 +/- 16% (p < 0.05) after IL-5. Treatment of guinea pigs with either the nonselective neurokinin (NK)-receptor antagonist, FK224, or the selective NK2-receptor antagonist, SR48968, results in a complete inhibition of the in vivo hyperresponsiveness found after application of IL-5. Vice versa, intra-airway administration of substance P (10 micrograms, twice) results in an airway hyperresponsiveness (increased maximal response after substance P: 166 +/- 15% [p < 0.05]) without inducing migration or activation of eosinophils. All examined NK-receptor antagonists do not influence the IL-5-induced eosinophil accumulation. In addition, no effect of the NK-receptor antagonists is observed on the IL-5-induced eosinophil activation, as determined by BAL fluid EPO levels. The release of NK2-receptor active tachykinins plays an important role in the development of IL-5-induced airway hyperresponsiveness. This feature appears to be a step following eosinophil infiltration and activation since there are no effects on eosinophil function by pretreatment of the used NK-receptor antagonists.
Author KRANEVELD, ALETTA D.
NIJKAMP, FRANS P.
VAN OOSTERHOUT, ANTOON J. M.
Author_xml – sequence: 1
  givenname: ALETTA D.
  surname: KRANEVELD
  fullname: KRANEVELD, ALETTA D.
  organization: Department of Pharmacology and Pathophysiology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
– sequence: 2
  givenname: FRANS P.
  surname: NIJKAMP
  fullname: NIJKAMP, FRANS P.
  organization: Department of Pharmacology and Pathophysiology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
– sequence: 3
  givenname: ANTOON J. M.
  surname: VAN OOSTERHOUT
  fullname: VAN OOSTERHOUT, ANTOON J. M.
  organization: Department of Pharmacology and Pathophysiology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2785401$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/9279211$$D View this record in MEDLINE/PubMed
BookMark eNp9kUFv1DAQhS1UVNrCPwDJB8Qti8dxnJhbVZW2UgWoAomb5TgTcMnawXaK9t_j1UY99NDTjOZ9b0aad0qOfPBIyFtgGwApPpr7aO12A43c8I2SrAMGL8gJNHVTCdWyo9Kztq6EUD9fkdOU7hkDXqhjcqx4qzjACXm4CxPSMUT6BZcY_jjvfMXpHVqcc5k6T298xjjhUrSqqZwfFosDPXfxn9nR692MMWKag0_uAT2mRPslUx8yvQzJ-TD_dpMz-0VXi_No6Df3K70mL0czJXyz1jPy4_Pl94vr6vbr1c3F-W1l6xpy1Q014IC1kYzbWlrJjbJ90yqwIKHtxSCRWzl0XBjedqMyXIKQthc9tl0j6jPy4bB3juHvginrrUsWp8l4DEvS5QtCtp0q4LsVXPotDnqObmviTq-PKvr7VTfJmmmMxluXHjG-v8b2mDhgNoaUIo6PBDC9T00fUtMlNc31mlqxfXpisy6b7ILP0bjpefN_iwygLQ
CitedBy_id crossref_primary_10_3390_ani11051376
crossref_primary_10_1152_ajplung_00179_2022
crossref_primary_10_1038_sj_bjp_0704310
crossref_primary_10_1016_S0014_2999_00_00546_X
crossref_primary_10_1002_bab_2533
crossref_primary_10_1146_annurev_immunol_17_1_255
crossref_primary_10_1034_j_1398_9995_2000_00112_x
crossref_primary_10_1152_ajpregu_00001_2002
crossref_primary_10_1046_j_1365_2222_2002_01328_x
crossref_primary_10_1016_j_ejphar_2005_12_066
crossref_primary_10_1046_j_1365_2222_1999_00683_x
crossref_primary_10_1084_jem_187_6_939
crossref_primary_10_1111_j_1365_2222_2006_02547_x
crossref_primary_10_1517_13543776_17_10_1241
crossref_primary_10_1111_j_1365_2222_2006_02549_x
crossref_primary_10_1164_ajrccm_161_6_9905039
crossref_primary_10_1016_j_crimmu_2021_06_001
crossref_primary_10_1016_j_resp_2007_08_004
crossref_primary_10_1517_13543776_11_7_1097
crossref_primary_10_1016_S0014_2999_01_01138_4
crossref_primary_10_1080_02770900701496080
crossref_primary_10_1016_S0014_2999_01_01323_1
crossref_primary_10_1016_S1567_5769_01_00099_6
crossref_primary_10_1164_ajrccm_159_5_9808058
crossref_primary_10_1016_S0014_2999_02_01365_1
crossref_primary_10_1016_S0192_0561_97_00085_4
crossref_primary_10_1067_mai_2000_106636
crossref_primary_10_1016_S1471_4892_01_00042_X
crossref_primary_10_1111_j_1365_2222_2008_03097_x
crossref_primary_10_1164_ajrccm_162_3_9910089
crossref_primary_10_1016_j_ejphar_2013_10_029
crossref_primary_10_1378_chest_123_2_524
crossref_primary_10_1038_sj_bjp_0705515
Cites_doi 10.1164/ajrccm.149.2.8306037
10.1172/JCI115166
10.1159/000235396
10.1164/ajrccm/148.4_Pt_1.927
10.1164/ajrccm.151.6.7767518
10.1164/ajrccm/148.6_Pt_1.1623
10.1111/j.1476-5381.1995.tb13220.x
10.1016/S0091-6749(95)70039-0
10.1016/0014-2999(93)90831-2
10.1183/09031936.96.09030493
10.1152/ajplegacy.1958.192.2.364
10.1183/09031936.93.04060673
10.1111/j.1476-5381.1992.tb14394.x
10.1016/0091-6749(93)90118-Y
10.1164/ajrccm/143.3.572
10.1164/ajrccm/144.5.1187
10.1164/ajrccm/148.4_Pt_1.915
10.3109/01902149109064334
10.1016/0014-2999(87)90244-5
10.1002/eji.1830190420
10.1165/ajrcmb.12.3.7873198
10.1164/ajrccm/147.4.982
10.1016/0022-1759(85)90242-X
10.1165/ajrcmb/7.6.631
10.1164/ajrccm.151.2.7531100
10.1006/pulp.1994.1020
10.1164/ajrccm/147.3.548
10.1164/ajrccm.153.1.8542107
10.1152/jappl.1994.77.3.1325
10.1016/0091-6749(92)90138-R
10.1182/blood.V73.6.1504.1504
10.1111/j.1432-1033.1993.tb17714.x
10.4049/jimmunol.145.8.2581
10.1136/thx.42.10.779
10.1172/JCI117594
10.1016/0143-4179(93)90048-F
10.1016/0091-6749(93)90085-T
10.1111/j.1365-2222.1993.tb02481.x
10.1016/0014-2999(93)90475-W
10.1164/ajrccm/146.1.148
10.1164/ajrccm/143.3.533
10.1182/blood.V79.12.3101.bloodjournal79123101
10.1164/ajrccm/144.2.368
10.1111/j.1476-5381.1995.tb15917.x
10.1155/S0962935194000098
10.1016/0091-6749(88)90230-8
10.1111/j.1476-5381.1993.tb13867.x
10.1111/j.1476-5381.1993.tb12888.x
ContentType Journal Article
Copyright 1997 INIST-CNRS
Copyright_xml – notice: 1997 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1164/ajrccm.156.2.9608101
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1535-4970
EndPage 374
ExternalDocumentID 9279211
2785401
10_1164_ajrccm_156_2_9608101
Genre Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GroupedDBID ---
-~X
.55
.GJ
0R~
1KJ
23M
2WC
3O-
53G
5GY
5RE
7RV
7X7
8C1
AAWTL
AAYXX
ABJNI
ABOCM
ABPMR
ACBNA
ACGFO
ACGFS
ADBBV
AENEX
AFCHL
AFFNX
AHMBA
AI.
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BENPR
C45
CITATION
CS3
DIK
E3Z
EBS
EJD
EX3
F5P
FRP
GX1
H13
HZ~
IH2
J5H
KQ8
L7B
M5~
N4W
O9-
OBH
OFXIZ
OGEVE
OK1
OVD
OVIDX
P2P
SJN
TEORI
THO
TR2
VH1
W8F
WH7
WOQ
WOW
X7M
ZGI
ZXP
~02
1CY
34G
39C
88E
8AO
8FI
8FJ
8FW
8R4
8R5
AAEJM
AAQQT
ABUWG
AFKRA
AFUWQ
AJJEV
AN0
BKEYQ
BNQBC
BPHCQ
BVXVI
CCPQU
EMOBN
FYUFA
HMCUK
IQODW
M1P
NAPCQ
OHT
PCD
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
Q2X
RWL
TAE
UKHRP
YJK
ZE2
3V.
ACRZS
CGR
CUY
CVF
ECM
EIF
NPM
RPM
VXZ
YCJ
7X8
ID FETCH-LOGICAL-c331t-8d31ede3a602c36c62a9cb5791c1617b4d6e2c6d824a278f9a26146cb4be78543
ISSN 1073-449X
IngestDate Thu Jul 10 17:50:57 EDT 2025
Wed Feb 19 01:13:04 EST 2025
Mon Jul 21 09:16:50 EDT 2025
Tue Jul 01 00:53:43 EDT 2025
Thu Apr 24 23:09:44 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Immunopathology
Allergy
Neurokinin 2
Hyperreactivity
Respiratory disease
Pathogenesis
Cytokine
Hemopathy
Eosinophilia
Asthma
Pig
Respiratory tract
Vertebrata
Mammalia
Interleukin 5
Animal
Artiodactyla
Obstructive pulmonary disease
Ungulata
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c331t-8d31ede3a602c36c62a9cb5791c1617b4d6e2c6d824a278f9a26146cb4be78543
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 9279211
PQID 79246789
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_79246789
pubmed_primary_9279211
pascalfrancis_primary_2785401
crossref_primary_10_1164_ajrccm_156_2_9608101
crossref_citationtrail_10_1164_ajrccm_156_2_9608101
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1997-08-01
PublicationDateYYYYMMDD 1997-08-01
PublicationDate_xml – month: 08
  year: 1997
  text: 1997-08-01
  day: 01
PublicationDecade 1990
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
PublicationTitle American journal of respiratory and critical care medicine
PublicationTitleAlternate Am J Respir Crit Care Med
PublicationYear 1997
Publisher American Lung Association
Publisher_xml – name: American Lung Association
References B20
Garland A. (B45) 1993; 147
B21
B22
B23
B24
B25
Bai T. R. (B43) 1995; 269
B26
B27
B28
B29
Fischer A. (B38) 1994; 149
B30
B32
B33
B34
B35
B36
B37
B39
B1
B2
B3
B4
B5
B6
B7
B8
B9
Ollerenshaw S. L. (B31) 1991; 4
B40
B41
B42
B46
B47
B48
B49
Kraneveld A. D. (B14) 1996; 153
B50
B51
B10
B11
B12
B13
B15
B16
B17
B18
B19
Kroegel C. (B44) 1990; 145
References_xml – ident: B49
  doi: 10.1164/ajrccm.149.2.8306037
– ident: B3
  doi: 10.1172/JCI115166
– ident: B33
  doi: 10.1159/000235396
– ident: B51
  doi: 10.1164/ajrccm/148.4_Pt_1.927
– ident: B50
  doi: 10.1164/ajrccm.151.6.7767518
– ident: B5
  doi: 10.1164/ajrccm/148.6_Pt_1.1623
– ident: B21
  doi: 10.1111/j.1476-5381.1995.tb13220.x
– ident: B12
  doi: 10.1016/S0091-6749(95)70039-0
– ident: B20
  doi: 10.1016/0014-2999(93)90831-2
– ident: B13
  doi: 10.1183/09031936.96.09030493
– ident: B24
  doi: 10.1152/ajplegacy.1958.192.2.364
– volume: 4
  start-page: 673
  year: 1991
  ident: B31
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.93.04060673
– ident: B27
  doi: 10.1111/j.1476-5381.1992.tb14394.x
– ident: B28
  doi: 10.1016/0091-6749(93)90118-Y
– ident: B36
  doi: 10.1164/ajrccm/143.3.572
– ident: B15
  doi: 10.1164/ajrccm/144.5.1187
– ident: B39
  doi: 10.1164/ajrccm/148.4_Pt_1.915
– ident: B37
  doi: 10.3109/01902149109064334
– ident: B40
  doi: 10.1016/0014-2999(87)90244-5
– ident: B8
  doi: 10.1002/eji.1830190420
– ident: B48
  doi: 10.1165/ajrcmb.12.3.7873198
– ident: B47
  doi: 10.1164/ajrccm/147.4.982
– ident: B25
  doi: 10.1016/0022-1759(85)90242-X
– ident: B10
  doi: 10.1165/ajrcmb/7.6.631
– ident: B34
  doi: 10.1164/ajrccm.151.2.7531100
– ident: B42
  doi: 10.1006/pulp.1994.1020
– ident: B4
  doi: 10.1164/ajrccm/147.3.548
– volume: 153
  start-page: A141
  year: 1996
  ident: B14
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/ajrccm.153.1.8542107
– ident: B35
  doi: 10.1152/jappl.1994.77.3.1325
– ident: B32
  doi: 10.1016/0091-6749(92)90138-R
– ident: B6
  doi: 10.1182/blood.V73.6.1504.1504
– volume: 147
  start-page: A816
  year: 1993
  ident: B45
  publication-title: Am. Rev. Respir. Dis.
– ident: B26
  doi: 10.1111/j.1432-1033.1993.tb17714.x
– volume: 145
  start-page: 2581
  year: 1990
  ident: B44
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.145.8.2581
– ident: B41
  doi: 10.1136/thx.42.10.779
– ident: B46
  doi: 10.1172/JCI117594
– ident: B18
  doi: 10.1016/0143-4179(93)90048-F
– volume: 269
  start-page: L309
  year: 1995
  ident: B43
  publication-title: Am. J. Physiol.
– ident: B29
  doi: 10.1016/0091-6749(93)90085-T
– ident: B30
  doi: 10.1111/j.1365-2222.1993.tb02481.x
– ident: B11
  doi: 10.1016/0014-2999(93)90475-W
– ident: B16
  doi: 10.1164/ajrccm/146.1.148
– ident: B2
  doi: 10.1164/ajrccm/143.3.533
– ident: B7
  doi: 10.1182/blood.V79.12.3101.bloodjournal79123101
– ident: B19
  doi: 10.1164/ajrccm/144.2.368
– ident: B17
  doi: 10.1111/j.1476-5381.1995.tb15917.x
– volume: 149
  start-page: A890
  year: 1994
  ident: B38
  publication-title: Am. J. Respir. Crit. Care Med.
– ident: B9
  doi: 10.1155/S0962935194000098
– ident: B1
  doi: 10.1016/0091-6749(88)90230-8
– ident: B22
  doi: 10.1111/j.1476-5381.1993.tb13867.x
– ident: B23
  doi: 10.1111/j.1476-5381.1993.tb12888.x
SSID ssj0012810
Score 1.7149007
Snippet In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma....
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 367
SubjectTerms Airway Resistance - drug effects
Animals
Biological and medical sciences
Bronchial Hyperreactivity - chemically induced
Bronchial Hyperreactivity - physiopathology
Bronchoalveolar Lavage Fluid - cytology
Chronic obstructive pulmonary disease, asthma
Dipeptides - pharmacology
Eosinophilia - chemically induced
Eosinophilia - physiopathology
Eosinophils - cytology
Eosinophils - drug effects
Eosinophils - physiology
Guinea Pigs
Indoles - pharmacology
Interleukin-5 - pharmacology
Leukocyte Count - drug effects
Male
Medical sciences
Peptides, Cyclic - pharmacology
Pneumology
Receptors, Neurokinin-2 - antagonists & inhibitors
Receptors, Neurokinin-2 - drug effects
Receptors, Neurokinin-2 - physiology
Specific Pathogen-Free Organisms
Substance P - pharmacology
Title Role for Neurokinin-2 Receptor in Interleukin-5-induced Airway Hyperresponsiveness but not Eosinophilia in Guinea Pigs
URI https://www.ncbi.nlm.nih.gov/pubmed/9279211
https://www.proquest.com/docview/79246789
Volume 156
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLaqISEkhLhNFBj4gbfIYbEdN3msGKhrtRaNDu0tchwHCiOt2gQEv40fx7HjpNkoGvASVWntRP6-Hp_jc0PoRRYLHskgJ1xmjPD4MCSRChSJc1AWtIYtT9lqn1MxOuPj8_C81_vZiVqqytRXP3bmlfwPqnAPcDVZsv-AbDsp3IDPgC9cAWG4_hXGpyY00MQJ2qqUn02vB0I9kGF6Vdo4c1sNYn2hK_iOhATs78r4--Vi_U1-9z6CDWp6c9ggWSf00qr0imXp6eVmUSxX5rhFmok-VKCOSm-1cOfqTeHaxuHTqUCx7njvbdZc003BRplddeZPTodT0wj0yEopfxuBPD0eT4Ynb6127W_T0N4Pp95s9g608NHsbO4GjX13qpu5hL5BGz1XdlIGTIviyh0DdTlZC2UQQ4Rz23J3K7XreuSOnrQjg1nd38Nt56xuAvT7TiG42QY_rZX64sNkPvXBmDPlzrY7YxMNcGXDbMMY6SAChRds7xsUjBTTP-PoeNL6sGjkamG4t3eJm_Dgl7see0kxur2SGwAmr5ur_Nn6sVrQ_C6648wXPKy5eA_1dHEf3TxxmD5AXw0lMVASdymJG0riRYF3UhLXlMQ7KImBkhgoibuUNBPVlMSGkg_R2ZvX81cj4lp7EMVYUJIoY4HONJPikComlKAyVmk4iANlDO6UZ0JTJbKIcgmrnMcSLH0uVMpTbRad7aO9YlnoRwiHlEkl5YAplXPNRZplucpSnYFlI3nI-4g165ooV_fetF-5SKz9K3hSo5EAGglNHBp9RNpRq7ruyzW_P7gEWTvIcaSPnjcQJiDAjVdOFnpZbZJBTEFZieI-2q-RbYfGprhnEDy-Zuon6Nb2f_UU7ZXrSh-AplymzywhfwESUsOk
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+for+neurokinin-2+receptor+in+interleukin-5-induced+airway+hyperresponsiveness+but+not+eosinophilia+in+guinea+pigs&rft.jtitle=American+journal+of+respiratory+and+critical+care+medicine&rft.au=KRANEVELD%2C+A.+D&rft.au=NIJKAMP%2C+F.+P&rft.au=VAN+OOSTERHOUT%2C+A.+J.+M&rft.date=1997-08-01&rft.pub=American+Lung+Association&rft.issn=1073-449X&rft.volume=156&rft.issue=2&rft.spage=367&rft.epage=374&rft_id=info:doi/10.1164%2Fajrccm.156.2.9608101&rft.externalDBID=n%2Fa&rft.externalDocID=2785401
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1073-449X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1073-449X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1073-449X&client=summon